Evidence mapPaperPMID 41495164Full record

ArticleNPJ digital medicine2026

Integrative single-cell and spatial transcriptomics with explainable AI reveal lethal prognostic axis in prostate cancer.

Qintao Ge, Zhenda Wang, Yangyun Wang, Tonghui Chu, Zhongyuan Wang, Wenkai Zhu, Youzhao Zhang, Yonghao Chen, Dingwei Ye, Wenhao Xu and 2 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qintao Ge *Department of Urology and Andrology, Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences; School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, PR China.
Zhenda Wang *Department of Urology and Andrology, Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences; School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, PR China.
Yangyun Wang *Department of Pelvic Floor Center, Shanghai Fifth People's Hospital Affiliated to Fudan University, Minhang District Pelvic Floor Center, Shanghai, China.
Tonghui Chu *Department of Urology and Andrology, Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences; School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, PR China.
Zhongyuan WangDepartment of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College; Qingdao Institute of Life Sciences, Fudan University, Shanghai, P.R. China.
Wenkai ZhuKashi Guangdong Institute of Science and Technology, The First People's Hospital of Kashi, Kashi, P.R. China.
Youzhao ZhangDepartment of Urology and Andrology, Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences; School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, PR China.
Yonghao ChenWest China Hospital of Sichuan University, Chengdu, P.R. China.
Dingwei YeDepartment of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College; Qingdao Institute of Life Sciences, Fudan University, Shanghai, P.R. China. dingwei_ye@fudan.edu.cn.
Wenhao XuDepartment of Urology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College; Qingdao Institute of Life Sciences, Fudan University, Shanghai, P.R. China. xwhao0407@163.com.
Zhong WangDepartment of Urology and Andrology, Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences; School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, PR China. wz08560@glhospital.com.
Mierxiati AbudurexitiDepartment of Urology and Andrology, Pudong Gongli Hospital, Shanghai University of Medicine & Health Sciences; School of Gongli Hospital Medical Technology, University of Shanghai for Science and Technology, Shanghai, PR China. mierxiati@fudan.edu.cn.

Funding

Key Discipline Development Initiative of the Shanghai Health System No. 2024ZDXK0043National Key Clinical Specialty Construction Project No. 10000015Z155080000004National Natural Science Foundation of China No. 82560609Natural Science Foundation of Xinjiang Uygur Autonomous Region, "Tianchi" talent introduction program No. 65310025P000013109145New Quality Clinical Specialty Program of High-end Medical Disciplinary Construction in Shanghai Pudong New Area No. 2024-PWXZ-13Project of the National Natural Science Foundation Cultivation Fund, Gongli Hospital, Pudong New Area No. 2024GPY-A03Science and Technology Program of Health Commission of Xinjiang Uygur Autonomous Region No.2025001QNKYXM653125763Shanghai Pudong New Area Science and Technology Development Fund "Medical and health special subproject" No. PKJ2023-Y28
6 · The paper itself

Abstract

Prostate cancer (PCa) remains clinically heterogeneous. We integrated single-cell and spatial transcriptomics with explainable machine learning to define a lethal tumor axis and establish an interpretable prognostic model. From 141,986 high-quality single cells spanning localized, hormone-sensitive, and castration-resistant PCa, we identified a malignant C4 epithelial subpopulation characterized by high chromosomal instability, androgen receptor and cell-cycle activation, and stemness potential. Spatial mapping further revealed immune-enriched yet suppressive niches, where fibroblasts and myeloid cells coexisted with exhausted lymphocytes, reflecting functional immune imbalance. We benchmarked 101 machine learning pipelines, selecting a Lasso plus PLS-Cox model that achieved strong concordance across independent cohorts. The C4-based risk score independently predicted recurrence-free survival after adjustment for age, Gleason score and T stage, and a nomogram combining this score with clinical variables showed good discrimination. SHAP interpretation highlighted MT1M, PCSK1N, and ACSL3 as major risk-driving features. PCSK1N was progressively upregulated from normal prostate to castration-resistant disease and promoted proliferation, clonogenicity, migration and enzalutamide resistance, while its inhibition sensitized organoids and xenografts to AR-targeted therapy. These findings define a C4-centered lethal tumor axis and provide an explainable, experimentally supported framework for prognostic stratification in PCa.

Identifiers

PMID41495164
PMCPMC12868606

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.